Clinical Observation of Candesartan Cilexetil Combined with Hydrochlorothiazide in the Treatment of Elder-ly Degenerative Valvular Heart Disease Heart Failure / 中国药房
China Pharmacy
; (12): 2922-2924, 2015.
Article
em Zh
| WPRIM
| ID: wpr-500807
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE:To observe the clinical efficacy and safety of candesartan cilexetil combined with hydrochlorothiazide in the treatment of elderly degenerative valvular heart disease heart failure. METHODS:120 patients with elderly degenerative val-vular heart disease heart failure were randomly divided into observation group,control group 1 and control group 2. All patients were given conventional treatment,including limited activity,limited salt,limited water,additional use of digitalis and nitrates car-diac drugs,etc. On this basis,observation group was orally treated with Candesartan cilexetil dispersible tablet 4 mg,once a day+Hydrochlorothiazide tablet 25 mg,once a day,took 10 d then stopped 2 d;control group 1 was orally treated with Enalapril male-ate tablet 10 mg,once a day+Hydrochlorothiazide tablet;control group 2 was orally treated with Metoprolol tartrate tablets 50 mg, twice a day+Hydrochlorothiazide tablet. All efficacies of patients were evaluated after one year,and the BNP,LVEF,LVEDD and SV before and after treatment,medication compliance and incidence of adverse reactions were observed. RESULTS:There was no significant difference in the total effective rate in each group(P>0.05). After treatment,the BNP and LVEDD were significantly lower than before,LVEF and SV were significantly higher than before,with significant difference(P0.05). CONCLUSIONS:Based on the conventional treatment,can-desartan cilexetil combined with hydrochlorothiazide has good clinical efficacy and safety in the treatment of elderly degenerative valvular heart disease heart failure.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
China Pharmacy
Ano de publicação:
2015
Tipo de documento:
Article